Trial Profile
An Open-label Study in Healthy Male Subjects, to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK961081, Administered as a Single Intravenous Microtracer (Concomitant With an Inhaled Non-radiolabelled Dose) and a Single Oral Dose
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Batefenterol (Primary) ; Batefenterol (Primary) ; Batefenterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Theravance Biopharma
- 07 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Mar 2016 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 05 Feb 2016 New trial record